Michael Ackermann - Jun 15, 2021 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Leo Greenstein
Stock symbol
TARS
Transactions as of
Jun 15, 2021
Transactions value $
$0
Form type
4
Date filed
6/17/2021, 07:19 PM
Next filing
Aug 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Award $0 +4.26K +0.35% $0.00 1.23M Jun 15, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +10K $0.00 10K Jun 15, 2021 Common Stock 10K $35.26 Direct F2
transaction TARS Stock Option (right to buy) Award $0 +10K $0.00 10K Jun 15, 2021 Common Stock 10K $35.26 Direct F3
transaction TARS Restricted Stock Units Award $0 +4.26K $0.00 4.26K Jun 15, 2021 Common Stock 4.26K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted restricted stock units ("RSUs") in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The RSUs are fully vested as of the date of grant.
F2 Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F3 Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.
F4 Each RSU represents a contingent right to receive one share of the Company's common stock.
F5 RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.